ICM
MDT icon

Invenomic Capital Management’s Medtronic MDT Stock Holding History

Invenomic Capital Management’s Portfolio MDT Stock Details MDT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-190,306
Closed -$15.3M – 148
2023
Q1 		$15.3M Buy
190,306
+55,789
+41% +$4.55M 0.87% 39
2022
Q4 		$10.5M Buy
+134,517
New +$10.9M 0.71% 49

Other funds holding MDT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Invenomic Capital Management's MDT Position: Q2 2023 in Review

Invenomic Capital Management sold out of Medtronic (MDT) in Q2 2023, closing a stake of 190,306 shares — an estimated $15.3M sold.

Invenomic Capital Management first reported a position in MDT in Q4 2022 and held it in 2 quarters. The position peaked at $15.3M in Q1 2023. 2,056 funds tracked by Wall St. Rank hold MDT as of Q2 2023.

  • Invenomic Capital Management reported no remaining Medtronic position as of Q2 2023 after selling out during the quarter.
  • Invenomic Capital Management sold 190,306 Medtronic shares in Q2 2023, an estimated $15.3M.
  • Invenomic Capital Management first reported a position in Medtronic in Q4 2022 and held it in 2 quarters.
  • Invenomic Capital Management's Medtronic position peaked at $15.3M in Q1 2023.
  • 2,056 funds tracked by Wall St. Rank held Medtronic as of Q2 2023.

Based on Invenomic Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.